Drug profile · INN
isavuconazonium sulfate
CRESEMBA
isavuconazonium sulfate (CRESEMBA) is a lanosterol 14-alpha demethylase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — isavuconazonium sulfate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
isavuconazonium sulfate (CRESEMBA) is a lanosterol 14-alpha demethylase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Lanosterol 14-alpha demethylase inhibitor
Primary target: Lanosterol 14-alpha demethylase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is isavuconazonium sulfate?
isavuconazonium sulfate (CRESEMBA) is a lanosterol 14-alpha demethylase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for isavuconazonium sulfate?
CRESEMBA is a marketed brand name for isavuconazonium sulfate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of isavuconazonium sulfate?
isavuconazonium sulfate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.